AZN Astrazeneca Plc - update on ultomiris phase III trial in hsct-tma Astrazeneca - ultomiris phase III trial in adults and adolescents with
AZN Astrazeneca Plc - update on ultomiris phase III trial in hsct-tma Astrazeneca - ultomiris phase III trial in adults and adolescents with hsct-tma did not meet primary endpoint - Ultomiris phase III trial in paediatric hsct-tma shows 87.2% survival at 26 weeks, 73.4% at 52 weeks - Advancing regulatory filings for ultomiris in paediatric hsct-tma - Ultomiris safety profile in trials consistent with known safety profile - Ultomiris granted orphan drug designation in US and Japan for hsct-tma - Ultomiris shows treatment benefit trend in adults and adolescents with hsct-tma; discussions ongoing
AZN Astrazeneca Plc - update on ultomiris phase III trial in hsct-tma Astrazeneca - ultomiris phase III trial in adults and adolescents with hsct-tma did not meet primary endpoint - Ultomiris phase III trial in paediatric hsct-tma shows 87.2% survival at 26 weeks, 73.4% at 52 weeks - Advancing regulatory filings for ultomiris in paediatric hsct-tma - Ultomiris safety profile in trials consistent with known safety profile - Ultomiris granted orphan drug designation in US and Japan for hsct-tma - Ultomiris shows treatment benefit trend in adults and adolescents with hsct-tma; discussions ongoing